What did @amanda.bynes1986 actually say?
The creator shared a weight update, saying she's down to 163 pounds after peaking at 180. She attributes the progress specifically to switching from what she calls an "Ozempic pill" to the Ozempic injection. Her goal is to lose 50 more pounds, and she frames the motivation as wanting to "feel skinny and cute." The update is personal and anecdotal, not a medical recommendation, to be fair.
She also mentions she gained weight initially, going from 173 to 180, which she implies happened while on the oral version before switching to injections. That's actually an important detail worth examining, because it touches on a real pharmacological question: does the delivery method matter?
Does the science back this up?
Here's where things get complicated. There is no FDA-approved oral version of semaglutide called "Ozempic." What exists is Rybelsus, an oral semaglutide tablet approved for type 2 diabetes, not weight loss. Wegovy is the injectable semaglutide approved for chronic weight management. Ozempic is an injectable approved for type 2 diabetes but widely prescribed off-label for weight loss.
The STEP trials (Wilding et al., 2021, New England Journal of Medicine) demonstrated that injectable semaglutide 2.4mg produces roughly 15% body weight reduction over 68 weeks. For oral semaglutide, a separate trial, the OASIS 1 study (Knop et al., 2023, The Lancet), showed about 15.1% weight reduction at the highest dose over 68 weeks. So the weight loss potential is actually comparable between delivery methods at appropriate doses, though bioavailability differs significantly. Oral semaglutide has only about 1% bioavailability compared to the injectable form.
What did they get wrong (or right)?
The claim that there's an "Ozempic pill" is inaccurate. Ozempic is only available as a subcutaneous injection. The oral semaglutide product is Rybelsus, a different brand entirely, though it contains the same active molecule. This is a meaningful distinction, not a pedantic one, because dosing, absorption, and approved indications differ between the two formulations.
What she got right: the injectable form of semaglutide does have more predictable pharmacokinetics. Oral semaglutide requires specific administration conditions, taken on an empty stomach with a small amount of water, and even then absorption varies considerably based on gastric pH and food timing (Buckley et al., 2018, Clinical Pharmacokinetics). If she was taking oral semaglutide incorrectly, switching to injections could genuinely improve efficacy. Her observation that the injection "is really working" for her is consistent with the clinical data on adherence and outcomes with injectables.
What should you actually know?
A few things worth keeping in mind if you're following GLP-1 content on TikTok. First, losing 17 pounds on semaglutide over an unspecified period is plausible and consistent with trial data, but individual results vary substantially based on dose, diet, activity level, and whether someone has insulin resistance or other metabolic conditions.
Second, the weight gain she described before switching, going from 173 to 180, is unusual and not a documented common effect of oral semaglutide. It's more likely explained by factors unrelated to the medication itself, such as dietary changes, fluid retention, or dose titration timing. GLP-1 receptor agonists do not typically cause weight gain as a side effect.
Third, framing weight loss motivation solely as wanting to "feel skinny and cute" is a personal choice, but for anyone considering GLP-1 therapy, the clinical decision should involve a prescribing provider who can evaluate BMI, comorbidities, and whether the medication's risk-benefit profile makes sense for you specifically. These are not lifestyle supplements.
- Semaglutide injections require cold storage and consistent weekly dosing schedules.
- Most insurance plans require a BMI of 30 or higher, or 27 with a weight-related condition, for coverage of Wegovy.
- Side effects including nausea, vomiting, and gastroparesis risk are real and should be discussed with a provider.